Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 maintenance therapy in high-risk locally advanced cervical cancer after chemoradiation
2018-002155-15Phase 2Active
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Cervical Cancer (CC) comparing TSR-042 maintenance therapy with Observation / standard follow-up (2 arms). Primary endpoint: Progression-free survival. Started May 2019; status: active.
02
Drugs
dostarlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-002155-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002155-15.